A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)

Clinical trial NCT06858813 · RECRUITING

Trial details

NCT number: NCT06858813
Sponsor: AbbVie
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Hepatocellular Cancer Squamous-Cell Non-Small Cell Lung Cancer

Start date: 2025-04-14
Primary completion: 2030-09-01
Enrollment: 232

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.